COPD GOLD Staging Calculator

Stage COPD using the GOLD framework, combining spirometric grade from FEV1 percent predicted with the ABE symptom and exacerbation groups.

🫁 Clinical Reference📐 GOLD grade from FEV1% predicted; ABE group from symptoms and exacerbations🏥 Health
FEV1 (% of predicted)
FEV1/FVC ratio (post-bronchodilator)
Symptom burden
Exacerbations in past year
Any exacerbation requiring hospitalisation
Please enter valid values.

Formula & Reference

VariableSymbolFormulaUnits
COPD GOLD Staging Calculator—GOLD grade from FEV1% predicted; ABE group from symptoms and exacerbationsgrade and group

Step-by-Step Examples

Example 1
Mild Disease

FEV1 84% predicted, ratio 0.66, low symptoms, no exacerbations.

  • FEV1 ≥ 80% → GOLD 1 (mild)
  • Ratio below 0.70 confirms airflow limitation
  • Low symptoms, no exacerbations → Group A
✓ GOLD 1 / Group A
Example 2
Moderate with Symptoms

FEV1 58% predicted, ratio 0.62, CAT 16, one exacerbation.

  • FEV1 50–79% → GOLD 2 (moderate)
  • CAT ≥ 10 → high symptom burden
  • One exacerbation, no hospitalisation → Group B
✓ GOLD 2 / Group B
Example 3
Severe with Exacerbations

FEV1 38% predicted, ratio 0.45, mMRC 3, three exacerbations with one hospitalisation.

  • FEV1 30–49% → GOLD 3 (severe)
  • Two or more exacerbations, plus a hospitalisation → Group E
  • Group E applies regardless of symptom score
✓ GOLD 3 / Group E

Real-World Applications

🫁
Treatment Selection
GOLD group, not spirometric grade, primarily determines initial inhaled therapy recommendations.
📊
Two-Dimensional Assessment
Airflow limitation and symptom or exacerbation burden correlate only loosely, which is why both axes are needed.
🏥
Exacerbation Prevention
Group E identifies patients whose dominant problem is exacerbation frequency rather than day-to-day symptoms.
📈
Disease Monitoring
Reassessing grade and group over time tracks progression and guides therapy escalation.

Common Mistakes to Avoid

⚠️
Diagnosing COPD from FEV1 alone

The spirometric diagnosis requires a post-bronchodilator FEV1/FVC ratio below 0.70. A reduced FEV1 with a normal ratio suggests a restrictive rather than obstructive pattern.

⚠️
Still using the ABCD groups

The 2023 GOLD revision merged the former groups C and D into a single Group E, since exacerbation risk drove management more than symptom level did.

⚠️
Assuming grade determines treatment

Initial pharmacological therapy is guided principally by ABE group. Spirometric grade informs prognosis and non-pharmacological decisions more than drug choice.

Frequently Asked Questions

What are the GOLD grades? ▾
GOLD 1 mild at FEV1 80% predicted or above, GOLD 2 moderate at 50–79%, GOLD 3 severe at 30–49%, and GOLD 4 very severe below 30%.
What are the GOLD ABE groups? ▾
Group A is low symptoms and low exacerbation risk, Group B is high symptoms with low exacerbation risk, and Group E is high exacerbation risk regardless of symptoms.
Why did GOLD replace ABCD with ABE? ▾
Because exacerbation history proved the stronger driver of treatment decisions, making the distinction between the former groups C and D of limited practical value.
What defines high exacerbation risk? ▾
Two or more moderate exacerbations in the past year, or at least one requiring hospitalisation.
Does the FEV1/FVC ratio need to be post-bronchodilator? ▾
Yes. The 0.70 threshold applies specifically to post-bronchodilator spirometry, which distinguishes fixed airflow limitation from reversible obstruction.

Related Health Calculators

🫁 Asthma Control Test🫁 CURB-65🫁 PSI / PORT Score🚨 NEWS2 Score🫁 VO2 Max